1. Central conducting lymphatic anomaly: from bench to bedside
- Author
-
Torales, Luciana Daniela Garlisi, Sempowski, Benjamin A., Krikorian, Georgia L., Woodis, Kristina M., Paulissen, Scott M., Smith, Christopher L., and Sheppard, Sarah E.
- Subjects
Tetracycline ,Genomics -- Genetic aspects ,Tetracyclines ,Health care industry - Abstract
Central conducting lymphatic anomaly (CCLA) is a complex lymphatic anomaly characterized by abnormalities of the central lymphatics and may present with nonimmune fetal hydrops, chylothorax, chylous ascites, or lymphedema. CCLA has historically been difficult to diagnose and treat; however, recent advances in imaging, such as dynamic contrast magnetic resonance lymphangiography, and in genomics, such as deep sequencing and utilization of cell-free DNA, have improved diagnosis and refined both genotype and phenotype. Furthermore, in vitro and in vivo models have confirmed genetic causes of CCLA, defined the underlying pathogenesis, and facilitated personalized medicine to improve outcomes. Basic, translational, and clinical science are essential for a bedside-to-bench and back approach for CCLA., Introduction The lymphatic system and its functions. The lymphatic system is a network of vessels and associated organs that play an essential role in human health by maintaining human tissue [...]
- Published
- 2024
- Full Text
- View/download PDF